[go: up one dir, main page]

EA201170753A1 - Налмефена гидрохлорид дигидрат - Google Patents

Налмефена гидрохлорид дигидрат

Info

Publication number
EA201170753A1
EA201170753A1 EA201170753A EA201170753A EA201170753A1 EA 201170753 A1 EA201170753 A1 EA 201170753A1 EA 201170753 A EA201170753 A EA 201170753A EA 201170753 A EA201170753 A EA 201170753A EA 201170753 A1 EA201170753 A1 EA 201170753A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrochloride dihydrate
nalmephena
nalmefene hydrochloride
dihydrate
pharmaceutical composition
Prior art date
Application number
EA201170753A
Other languages
English (en)
Other versions
EA018948B1 (ru
Inventor
Хейди Лопес Де Диего
Карла Де Фавери
Флориан Антон Мартин Хубер
Original Assignee
Х. Лундбекк А/С
Байотай Терапис Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170753(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С, Байотай Терапис Корп. filed Critical Х. Лундбекк А/С
Publication of EA201170753A1 publication Critical patent/EA201170753A1/ru
Publication of EA018948B1 publication Critical patent/EA018948B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к налмефена гидрохлорид дигидрату, способам получения налмефена гидрохлорид дигидрата, фармацевтической композиции, содержащей налмефена гидрохлорид дигидрат, и способам лечения, включающим назначение к приему налмефена гидрохлорид дигидрата.
EA201170753A 2008-12-05 2009-12-04 Налмефена гидрохлорид дигидрат EA018948B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05
PCT/DK2009/050320 WO2010063292A1 (en) 2008-12-05 2009-12-04 Nalmefene hydrochloride dihydrate

Publications (2)

Publication Number Publication Date
EA201170753A1 true EA201170753A1 (ru) 2011-12-30
EA018948B1 EA018948B1 (ru) 2013-11-29

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170753A EA018948B1 (ru) 2008-12-05 2009-12-04 Налмефена гидрохлорид дигидрат

Country Status (30)

Country Link
US (2) US8530495B2 (ru)
EP (2) EP2441766B1 (ru)
JP (3) JP6055183B2 (ru)
KR (2) KR20110089333A (ru)
CN (2) CN104211707B (ru)
AR (1) AR074507A1 (ru)
AT (1) ATE546453T1 (ru)
AU (1) AU2009321898B2 (ru)
BR (1) BRPI0922774B8 (ru)
CA (1) CA2744932C (ru)
CL (1) CL2011001331A1 (ru)
CO (1) CO6362012A2 (ru)
CY (2) CY1112643T1 (ru)
DK (2) DK2441766T3 (ru)
EA (1) EA018948B1 (ru)
ES (2) ES2380297T3 (ru)
HR (2) HRP20120247T1 (ru)
IL (1) IL213112A (ru)
MX (1) MX2011005865A (ru)
MY (1) MY149028A (ru)
NZ (1) NZ593874A (ru)
PL (2) PL2300479T3 (ru)
PT (2) PT2300479E (ru)
RS (2) RS53415B (ru)
SG (1) SG171910A1 (ru)
SI (2) SI2441766T1 (ru)
SM (2) SMT201200014B (ru)
TW (1) TWI465450B (ru)
UA (1) UA102128C2 (ru)
WO (1) WO2010063292A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6479766B2 (ja) * 2013-04-17 2019-03-06 ハー・ルンドベック・アクチエゼルスカベット 不安障害患者の治療のためのナルメフェン
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
AR100153A1 (es) 2014-04-22 2016-09-14 Otsuka Pharma Co Ltd Medicamento
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
DK1708690T3 (en) * 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CA2680205C (en) * 2007-03-06 2015-06-30 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
WO2008127618A1 (en) * 2007-04-12 2008-10-23 Mallinckrodt Inc. Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
PT2300479E (pt) 2012-04-10
SG171910A1 (en) 2011-07-28
SI2300479T1 (sl) 2012-07-31
MY149028A (en) 2013-06-28
ES2380297T3 (es) 2012-05-10
US8754217B2 (en) 2014-06-17
BRPI0922774B1 (pt) 2020-10-13
CO6362012A2 (es) 2012-01-20
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
EA018948B1 (ru) 2013-11-29
PL2441766T3 (pl) 2014-09-30
CY1112643T1 (el) 2016-02-10
SMT201400113B (it) 2014-11-10
JP2012510954A (ja) 2012-05-17
EP2441766A1 (en) 2012-04-18
MX2011005865A (es) 2011-09-06
EP2441766B1 (en) 2014-06-25
CN102325778A (zh) 2012-01-18
CN102325778B (zh) 2014-08-13
PL2300479T3 (pl) 2012-06-29
HRP20120247T1 (hr) 2012-05-31
HRP20140648T1 (hr) 2014-09-26
EP2300479A1 (en) 2011-03-30
KR20110089333A (ko) 2011-08-05
AU2009321898A1 (en) 2011-07-14
TW201022273A (en) 2010-06-16
IL213112A0 (en) 2011-07-31
AR074507A1 (es) 2011-01-19
JP6591759B2 (ja) 2019-10-16
BRPI0922774B8 (pt) 2021-05-25
SI2441766T1 (sl) 2014-12-31
UA102128C2 (en) 2013-06-10
DK2300479T3 (da) 2012-03-26
RS53415B (en) 2014-12-31
US20110251228A1 (en) 2011-10-13
EP2300479B1 (en) 2012-02-22
NZ593874A (en) 2013-02-22
CA2744932A1 (en) 2010-06-10
ES2488165T3 (es) 2014-08-26
US20130338365A1 (en) 2013-12-19
US8530495B2 (en) 2013-09-10
DK2441766T3 (da) 2014-07-21
PT2441766E (pt) 2014-08-05
RS52255B (en) 2012-10-31
TWI465450B (zh) 2014-12-21
KR20170008893A (ko) 2017-01-24
CL2011001331A1 (es) 2011-08-26
CY1115381T1 (el) 2017-01-04
BRPI0922774A2 (pt) 2017-07-11
CN104211707B (zh) 2017-04-12
JP2017025079A (ja) 2017-02-02
JP2015134785A (ja) 2015-07-27
JP6591944B2 (ja) 2019-10-16
WO2010063292A1 (en) 2010-06-10
AU2009321898B2 (en) 2014-10-02
JP6055183B2 (ja) 2016-12-27
IL213112A (en) 2013-06-27
ATE546453T1 (de) 2012-03-15
HK1205108A1 (en) 2015-12-11
SMT201200014B (it) 2012-07-10

Similar Documents

Publication Publication Date Title
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA200802324A1 (ru) Новая форма введения рацекадотрила
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EA201190312A1 (ru) Замещенные пиперидины
EA200900463A1 (ru) Арипипразола гемифумарат и способ его получения
EA201171414A1 (ru) Ингибиторы белков семейства iap
EA201001353A1 (ru) Гидробромид ивабрадина
EA200970816A1 (ru) Новая лекарственная форма
EA201190313A1 (ru) Замещенные пиперидины
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY